



Attorney Docket No.: 6569.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Jeppesen et al.

Confirmation No.: 1686

Application No.: 10/693,161

Group Art Unit: 1626

Filed: October 24, 2003

Examiner: Paviglianiti, Anthony

For: Novel Compounds, Their Preparation and Use

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US 2004 0143006
2. US 2005 0080115

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

Attorney Docket No.: 6569.200-US
Express Mail Label No. EV 246879087 US
Application No.: 10/693,161
Filed: October 24, 2003
Applicants: Jeppesen et al.

This information disclosure statement is being filed **after** the mailing date of any of a final action under 37 C.F.R. § 1.113, a notice of allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, but before, or simultaneously with, the payment of the issue fee.

Accompanying this information disclosure statement is the fee set forth in § 1.17(p) (currently \$180.00). The Examiner is hereby authorized to charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Please charge any additional fees, should they be required, to Novo Nordisk Inc. Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Date: November 15, 2005

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Customer Number

23650

PATENT TRADEMARK OFFICE

FORM PTO 449 (Rev. 2-32) NOV 15 2005 U.S. PATENT & TRADEMARK OFFICE	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6569.200-US	Serial No. 10/693,161
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
	Applicant Jeppesen et al.		Filing Date October 24, 2003

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2004 0143006	7/22/04	Jeppesen et al.	514	485	
	2005 0080115	4/14/05	Jeppesen et al.	514	357	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.